CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in '65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report
Bibliographic record
Abstract
Abstract Abstract 254 Background: CPX-351 is a liposomal formulation containing a 5:1 molar ratio of cytarabine (Ara-C) and daunorubicin (DNR) shown to maximize anti-tumor synergy. Preclinical studies demonstrated accumulation of CPX-351 within bone marrow with preferential uptake of liposomes by leukemia cells. A Phase 1 study using 90-minute I.V. infusions on Days 1, 3, and 5 found the MTD to be 101 u/m2 (1 u = 1 mg Ara-C + 0.44 mg DNR) and demonstrated marked prolongation of plasma Ara-C and DNR half-life. Eighteen of the 45 AML patients were in 1st relapse with 8 patients <65 years of age. All 8 achieved aplasia and 4/8 achieved CR after CPX-351. (Feldman E, et al. Blood 2008;112:Abst 2984). On this basis, a randomized Phase 2b study was initiated in first relapse AML patients comparing CPX-351 against investigator's choice of salvage regimen. This report summarizes initial safety and response data for patients randomized and followed >60 days. Methods: Patients ≤65yo with AML in 1st relapse after an initial CR lasting >1 month with ECOG PS= 0–2, SCr < 2.0 mg/dL, total bilirubin < 2.0 mg/dL, ALT/AST < 3 × ULN, and LVEF > 50% were eligible. Patients were randomized 2:1 to receive CPX-351 (100 u/m2; D 1, 3, 5) or investigators choice of intensive salvage treatment. Up to 2 inductions and 2 consolidation courses were allowed. Post remission treatment with hematopoietic stem cell transplantation (HSCT) was permitted. Patients were stratified using the European Prognostic Index (EPI) (Breems DA, et al. J Clin Oncol, 2005 Mar 20;23:1969–1978). The primary efficacy endpoint is % survival at 1-year and 2° efficacy endpoints include CR+ CRi rate, CR+ CRi duration, EFS, aplasia rate (<5% blasts + <20% cellularity), and % referred for HSCT. Deaths at Day 30 and 60 and SAE frequency were monitored. Results: As of November 12, 2010, 126 patients were accrued at 35 of 46 sites in the US, Canada, France and Poland. 94% had received prior anthracycline therapy. Most patients had a single induction (88% v. 93%) and salvage consisted mostly of MEC (51%) or 7+3 (16%). Demographic and EPI risk factors were well balanced except for prior HSCT (27% (CPX-351) vs. 18% (7+3)). Compared to control, CPX-351 had greater anti-leukemia activity based on rate of aplasia (90% vs. 60%) and CR + CRi rate (51% vs. 42%). A greater response improvement with CPX-351 vs. control was observed in the EPI unfavorable group (23/56 (41.1%) vs. 9/30 (30%))as well as in patients with no history of prior HSCT (56% vs. 41%). Early deaths ( Conclusion: In this Phase 2b randomized trial, CPX-351 has substantial clinical activity and is safe compared to salvage therapy. Improved efficacy was observed in patients with unfavorable EPI scores and in those with no history of HSCT. Longer myelosuppression with CPX-351 led to increased febrile neutropenia and infections. These initial data support further investigation of CPX-351 in first relapse AML patients. This study is expected to be completed in November 2011 and final results (including EFS + OS analyses) will be available at that time. Disclosures: Cortes: Celator: Membership on an entity's Board of Directors or advisory committees. Paulsen:Celator Pharmaceuticals: Employment. Louie:Celator: Employment.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".